What the research found

Researchers reviewed real-world records from 60 patients who started compounded tirzepatide at doses of 1–2 mg weekly—substantially lower than the standard 2.5 mg starting dose. Weight loss appeared to accumulate gradually: roughly 2% in the first three weeks, 3.6% by weeks 5–8, and 6% by weeks 9–12. The pattern suggested a consistent rate of loss across the observation period, estimated at about 2 percentage points per month of treatment.

The cohort was predominantly female (82%), middle-aged (mean 47 years), and started with a mean BMI of 33.3 kg/m². All had documented baseline weights and treatment records; measurements were taken at defined intervals to reduce noise. The researchers used a statistical model to estimate the trajectory, but acknowledge the data become sparse at longer timepoints—only 8 patients had follow-up in the 60–89 day window.

Why it matters for you

If you're considering or using tirzepatide for weight management, this flags that lower starting doses than the standard 2.5 mg do produce meaningful weight loss, even if onset is gradual. For someone risk-averse about side effects (nausea, appetite suppression), a 1–2 mg initiation might offer a gentler entry while still moving the needle on body composition over 2–3 months.

The data also contextualises what "slow" actually looks like: 2% in three weeks is modest but detectable on a scale or in how clothes fit. If you're tracking biomarkers like fasting glucose, lipids, or inflammatory markers, those often shift before dramatic weight loss becomes visible. This microdose window might be where you observe metabolic changes without the intensity of higher doses.

That said, these are compounded (non-branded) preparations, which may differ in consistency or purity from Mounjaro. The cohort is also heavily skewed female and wasn't compared to placebo or standard dosing, so it's unclear whether 1–2 mg is genuinely effective or simply captures initial expectancy effects.

Caveats

  • Observational, uncontrolled: No comparison arm; weight loss could partly reflect diet, exercise, or measurement timing rather than the drug alone.
  • Sparse longer-term data: Only 8 patients in the 60–89 day group; the 6% estimate has wide confidence intervals and may not be reliable.
  • Compounded product: Pharmacy-prepared tirzepatide; consistency and bioavailability may differ from branded formulations.
  • Female-skewed sample (82% female); generalisability to men unclear.
  • Hypothesis-generating: Authors explicitly frame this as preliminary; no pre-registered analysis or sample-size justification.